Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2022

View Archived Issues

BLU-945 for treatment-resistant EGFR T790M mutation-driven lung cancer

Medshine Discovery divulges thyroid hormone receptor beta agonists

Galderma discovers JAK-1 inhibitors

New NFE2-related factor 2 activators described by Sanofi

CNRS and collaborators patent acetylcholinesterase reactivators

RemeGen discloses new anti-c-Met antibody-drug conjugates

Telomere to telomere, the human genome is done

Novel humanized HIS-BRGS mouse model to evaluate immune-related kidney toxicities

New orthotopic xenograft breast cancer murine models developed

Humanized mouse model to asses acute toxicity of immune drug treatments

Sosei Heptares presents novel GLP-1 receptor antagonist HTL-0033097

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...